Sunshine Biopharma Inc. cash flow statement
In fiscal 2025, Sunshine Biopharma Inc.'s operations generated −$5.3m of cash; it spent $174,491 on capital projects, leaving free cash flow of −$5.5m.
Cash flow statement
| Fiscal year | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1 | −1 | −0 | −1 | −2 | −5 | −9 | −13 | −5 | −5 |
| Depreciation and amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based pay | 1 | 1 | 0 | 0 | — | — | — | — | — | — |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Free cash flow | −1 | −1 | −0 | −1 | −2 | −5 | −9 | −14 | −6 | −5 |
| Free cash flow after stock pay | −1 | −1 | −1 | −1 | — | — | — | — | — | — |
| Share buybacks | — | — | — | — | — | — | 1 | 3 | 0 | — |
| Shares issued | 0 | 0 | — | — | 0 | 30 | 4 | 9 | 2 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −1,357 | −3,405 | −1,695 | −1,273 | −747 | −1,616 | −2,072 | −918 |
| Depreciation and amortisation | 65 | 65 | 65 | 73 | 96 | 99 | 77 | 78 |
| Capital spending | 517 | 103 | 7 | 160 | 8 | −1 | 5 | 7 |
| Free cash flow | −1,874 | −3,508 | −1,702 | −1,433 | −755 | −1,615 | −2,077 | −925 |
| Shares issued | 0 | 0 | 0 | 1,829 | 0 | 0 | — | — |
Compare with peers
- BGM Group Ltd. cash flow
- IM Cannabis Corp. cash flow
- Scilex Holding Co cash flow
- Cumberland Pharmaceuticals Inc cash flow
- Verrica Pharmaceuticals Inc. cash flow
Head to head: BGM vs SBFMIMCC vs SBFMSBFM vs SCLXCPIX vs SBFM
More: Pharmaceuticals stocks compared, Health Care sector, rankings of US companies